Ernexa Therapeutics Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Ernexa Therapeutics Inc. (ERNA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.15% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-13
- Ernexa Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.15%.
- Ernexa Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.05%.
- Ernexa Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.74%, a 112.15% decline from fiscal 2022.
- Ernexa Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 6.09%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -0.15% 10-K · filed 2026-03-13 | |
| 2024-12-31 | -0.05% 10-K · filed 2026-03-13 | |
| 2023-12-31 | -0.74% 10-K · filed 2025-03-12 | |
| 2022-12-31 | 6.09% 10-K · filed 2024-03-14 | |
| 2021-12-31 | -16.30% 10-K · filed 2023-03-20 | -16.33% 10-K · filed 2022-04-15 |
| 2020-12-31 | 0.00% 10-K/A · filed 2022-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |